The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
‘Metabolically healthy obesity’: Origins and implications
Open accessAbstract
When humans eat more and exercise less, they tend to become obese and unhealthy. The molecular pathways that link obesity to serious diseases like Type 2 diabetes and cardiovascular disease have become a subject of intensive scientific investigation because the exploding prevalence of obesity worldwide represents a grave new threat to the health of hundreds of millions of people. However, obesity is not always destiny. Two important clinical populations have been valuable to understand the mechanisms behind this conundrum: individuals who exhibit metabolic dysfunction, diabetes and elevated cardiovascular disease risk despite a lean body type, and individuals who are relatively protected from these dangers despite significant obesity. Study of this second group of ‘metabolically healthy obese’ people in particular has been revealing because such individuals exhibit specific, identifiable, anatomic, cellular and molecular features that set them apart from the rest of us who suffer declining health with increasing weight. Here, we examine some of these features, including some mouse models that are informative of mechanism, and suggest hypotheses for further study, including the possibility that genes and pathways of the immune system might offer new diagnostic or therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760 · cited 6×
“Collagen VI deposition and AT fibrosis in human WAT is coincident with the presence of ‘alternatively activated’ (CD150+) adipose tissue macrophages (ATMs) that are known to promote ECM remodeling and wound healing (Spencer et al., 2010; see also Shaul et al., 2010).”
BackgroundInfluentialInflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Finucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., Singh, G. M., Gutierrez, H. R., Lu, Y., Bahalim, A. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62037-5 · Cited by 4,050
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855 · cited 2×
“Obesity also promotes cardiovascular disease (CVD), hypertension, stroke and cancer (Van Gaal et al., 2006; Guh et al., 2009).”
BackgroundSubcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697 · cited 1×
“7 mmol/liter; high-density lipoprotein-cholesterol <1.0 mmol/liter (in men) or <1.3 mmol/liter (in women); and blood pressure P130/85 mmHg or current treatment for hypertension (Grundy et al., 2005; Janiszewski and Ross, 2010).”
BackgroundInfluentialCinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, A. S., & Obin, M. S. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500294-jlr200 · Cited by 2,529
Self-citationDynamics of fat cell turnover in humans
Spalding, K. L., Arner, E., Westermark, P. O., Bernard, S., Buchholz, B. A., Bergmann, O., Blomqvist, L., Hoffstedt, J., Näslund, E., Britton, T., et al. (2008) · Nature · doi:10.1038/nature06902 · Cited by 2,357
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Wildman, R. P. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.15.1617 · Cited by 1,618 · cited 1×
“This group, which also displays an absence of dyslipidemia, hyperuricemia and hypertension (Bonora et al., 1991; Wildman et al., 2008) has been thought of as ‘metabolically healthy obese’ (MHO, Fig.”
BackgroundPolycystic ovary syndrome: etiology, pathogenesis and diagnosis
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.217 · Cited by 1,488 · cited 2×
“For example, PCOS has been diagnosed in up to 10% of one study of women of reproductive age (Goodarzi et al., 2011) and MONW in 12.7% of normal-weight subjects in a Korean study (Lee, 2009).”
BackgroundInfluentialObesity-associated improvements in metabolic profile through expansion of adipose tissue
Kim, J.-Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M. E., Hofmann, S. M., Schraw, T., Durand, J. L., Li, H., Li, G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31021 · Cited by 1,310 · cited 1×
“Adiponectin transgenic mice on an ob/ob background (AdTg) have 2- to 3-fold higher levels of circulating adiponectin than ob/ob controls (Kim et al., 2007).”
BackgroundRelationship between Adipocyte Size and Adipokine Expression and Secretion
Skurk, T., Alberti-Huber, C., Herder, C., & Hauner, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1055 · Cited by 1,288
Metabolic Dysregulation and Adipose Tissue Fibrosis: Role of Collagen VI
Khan, T., Muise, E. S., Iyengar, P., Wang, Z. V., Chandalia, M., Abate, N., Zhang, B. B., Bonaldo, P., Chua, S., & Scherer, P. E. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01300-08 · Cited by 1,053
Adiponectin and AdipoR1 Regulate PGC-1α and Mitochondria by Ca2+ and AMPK/SIRT1
Iwabu, M., Yamauchi, T., Okada-Iwabu, M., Sato, K., Nakagawa, T., Funata, M., Yamaguchi, M., Namiki, S., Nakayama, R., Tabata, M., et al. (2010) · Nature · doi:10.1038/nature08991 · Cited by 971
Hypoxia-Inducible Factor 1α Induces Fibrosis and Insulin Resistance in White Adipose Tissue
Halberg, N., Khan, T., Trujillo, M. E., Wernstedt-Asterholm, I., Attie, A. D., Sherwani, S., Wang, Z. V., Landskroner-Eiger, S., Dineen, S., Magalang, U. J., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00192-09 · Cited by 896 · cited 1×
“…and other ECM components (i.e., fibrosis) eventually constrains adipocyte expansion, thereby promoting adipocyte stress, inflammatory/stress kinase activation and resulting AT and systemic metabolic dysfunction (Henegar et al., 2008; Halberg et al., 2009; Khan et al., 2009; Divoux et al., 2010).”
BackgroundThe metabolically obese, normal-weight individual revisited.
Ruderman, N., Chisholm, D., Pi-Sunyer, X., & Schneider, S. (1998) · Diabetes · doi:10.2337/diabetes.47.5.699 · Cited by 893
Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin
Holland, W. L., Miller, R. A., Wang, Z. V., Sun, K., Barth, B. M., Bui, H. H., Davis, K. E., Bikman, B. T., Halberg, N., Rutkowski, J. M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2277 · Cited by 892
Klöting, N., Fasshauer, M., Dietrich, A., Kovacs, P., Schön, M. R., Kern, M., Stumvoll, M., & Blüher, M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00586.2009 · Cited by 856
de Bakker, P. I. W., McVean, G., Sabeti, P. C., Miretti, M. M., Green, T., Marchini, J., Ke, X., Monsuur, A. J., Whittaker, P., Delgado, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1885 · Cited by 766
Kintscher, U., Hartge, M., Hess, K., Foryst-Ludwig, A., Clemenz, M., Wabitsch, M., Fischer-Posovszky, P., Barth, T. F. E., Dragun, D., Skurk, T., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.165100 · Cited by 692
Adiponectin Promotes Macrophage Polarization toward an Anti-inflammatory Phenotype
Ohashi, K., Parker, J. L., Ouchi, N., Higuchi, A., Vita, J. A., Gokce, N., Pedersen, A. A., Kalthoff, C., Tullin, S., Sams, A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.088708 · Cited by 646 · cited 1×
“Several genes in the MHC are likely candidates, including LTA, which encodes lymphotoxin-a and is important for the inflammatory component of coronary artery disease (Ozaki et al., 2002); TNF, BRD2 and HLA-DRB1.”
BackgroundThe distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals
Blüher, M. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283346ccc · Cited by 632
The metabolically healthy but obese individual presents a favorable inflammation profile
Karelis, A. D., Faraj, M., Bastard, J.-P., St-Pierre, D. H., Brochu, M., Prud’homme, D., & Rabasa-Lhoret, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0482 · Cited by 579
Combs, T. P., Pajvani, U. B., Berg, A. H., Lin, Y., Jelicks, L. A., Laplante, M., Nawrocki, A. R., Rajala, M. W., Parlow, A. F., Cheeseboro, L., et al. (2004) · Endocrinology · doi:10.1210/en.2003-1068 · Cited by 545
The “metabolically-obese,” normal-weight individual
Ruderman, N. B., Schneider, S. H., & Berchtold, P. (1981) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/34.8.1617 · Cited by 545
Kim, C.-S., Park, H.-S., Kawada, T., Kim, J.-H., Lim, D., Hubbard, N. E., Kwon, B.-S., Erickson, K. L., & Yu, R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803259 · Cited by 511
Henegar, C., Tordjman, J., Achard, V., Lacasa, D., Cremer, I., Guerre-Millo, M., Poitou, C., Basdevant, A., Stich, V., Viguerie, N., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-1-r14 · Cited by 471
Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease
Matsuzawa, Y. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0380 · Cited by 434 · cited 1×
“A more precise term might be ‘metabolically protected obese’ because not only are a number of deleterious factors reduced in these individuals, but other protective factors are relatively undiminished, such as serum adiponectin (Berg and Scherer, 2005; Matsuzawa, 2006).”
BackgroundA Pericellular Collagenase Directs the 3-Dimensional Development of White Adipose Tissue
Chun, T.-H., Hotary, K. B., Sabeh, F., Saltiel, A. R., Allen, E. D., & Weiss, S. J. (2006) · Cell · doi:10.1016/j.cell.2006.02.050 · Cited by 378
Why Visceral Fat is Bad: Mechanisms of the Metabolic Syndrome
Bergman, R. N., Kim, S. P., Catalano, K. J., Hsu, I. R., Chiu, J. D., Kabir, M., Hucking, K., & Ader, M. (2006) · Obesity · doi:10.1038/oby.2006.277 · Cited by 371
Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis
Toulis, K. A., Goulis, D. G., Farmakiotis, D., Georgopoulos, N. A., Katsikis, I., Tarlatzis, B. C., Papadimas, I., & Panidis, D. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp006 · Cited by 262
Côté, M., Mauriège, P., Bergeron, J., Alméras, N., Tremblay, A., Lemieux, I., & Després, J.-P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1711 · Cited by 230
Brd2 disruption in mice causes severe obesity without Type 2 diabetes
Wang, F., Liu, H., Blanton, W. P., Belkina, A., Lebrasseur, N. K., & Denis, G. V. (2010) · Biochemical Journal · doi:10.1042/bj20090928 · Cited by 185
Self-citationInflammation, adiponectin, obesity and cardiovascular risk
Mangge, H., Almer, G., Truschnig-Wilders, M., Schmidt, A., Gasser, R., & Fuchs, D. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710794183006 · Cited by 142 · cited 2×
“, 2010) and IR likely co-vary and contribute to common comorbidities, such as CVD and atherosclerosis that is prevalent among obese IR patients (Mangge et al., 2010; Westlake et al., 2011).”
BackgroundChutkow, W. A., Birkenfeld, A. L., Brown, J. D., Lee, H.-Y., Frederick, D. W., Yoshioka, J., Patwari, P., Kursawe, R., Cushman, S. W., Plutzky, J., et al. (2010) · Diabetes · doi:10.2337/db09-1212 · Cited by 142
Cited by
What we talk about when we talk about fat
Rosen, E. D., & Spiegelman, B. M. (2014) · Cell · doi:10.1016/j.cell.2013.12.012 · Cited by 2,373
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation
Iyengar, N. M., Gucalp, A., Dannenberg, A. J., & Hudis, C. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4283 · Cited by 1,004
Metabolically healthy obesity: Epidemiology, mechanisms, and clinical implications
Stefan, N., Häring, H.-U., Hu, F. B., & Schulze, M. B. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70062-7 · Cited by 857
Targeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678
Metadata
- Authors
- Denis, G. V., & Obin, M. S.
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 34
- Issue
- 1
- Pages
- 59-70
- ISSN
- 0098-2997 (ISSN-L)
- OpenAlex
- W2065170163
- Cited by
- 169
- References
- 39
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.